ClinicalTrials.gg
RecruitingNCT06289491Updated Mar 30, 2026

A Trial of Hydrus Microstent Versus Goniotomy

An interventional study of Hydrus Microstent and Incisional goniotomy in Glaucoma and Glaucoma, Open-Angle, sponsored by Massachusetts Eye and Ear Infirmary. Recruiting at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Primary conditionGlaucoma, Open-AngleRegistry: GlaucomaReclassifiedWhy we changed it
Registry
Glaucoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Glaucoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts Eye and Ear Infirmary · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are:

  • How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare?
  • How do the safety profiles of these three microinvasive glaucoma surgeries compare?

Participants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.

02

Conditions studied

  • Glaucoma
  • Glaucoma, Open-Angle

Browse trials for

Keywords

  • Incisional goniotomy
  • Excisional goniotomy
  • Hydrus Microstent
  • Goniotomy
03

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.

This study's planned enrollment of 243 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Massachusetts Eye and Ear Infirmary is the lead sponsor of 100 studies on the registry; 23 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visually significant cataract planned for surgery
  • Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma
  • Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees \<15 dB
  • Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points \<15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point \<15 dB
  • Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery
  • Willing and able to understand and provide
  • Willing and able to attend postoperative examinations per protocol schedule

Exclusion criteria

Exclusion Criteria:

  • Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation
  • Selective laser trabeculoplasty within 90 days of study enrollment
  • Iridotrabecular contact for 180 degrees or greater
  • Peripheral anterior synechiae in nasal or inferior angle
  • Best corrected visual acuity worse than 20/200
  • Phacodonesis on pre-operative examination
  • Vitreous in anterior chamber on pre-operative examination
  • Nanophthalmos
  • Anti- and anticoagulant medications other than aspirin 81mg daily
  • Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, for corneal transplant)
  • Abnormality in study eye that could affect tonometry
  • Glaucoma diagnosis other than the above
  • Normal tension glaucoma
  • Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor)
  • History of uveitis in either eye
  • Inability to complete gonioscopy examination
  • Use of oral steroids within 90 days or anticipated use of oral steroids
  • Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide
  • History of steroid-associated IOP elevation
  • Medically unfit for attending planned study visits
  • Involvement in another interventional research study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (estimated)

Study arms

  • Experimental
    Hydrus Microstent

    Procedure: Hydrus Microstent

  • Experimental
    Incisional goniotomy

    Procedure: Incisional goniotomy

  • Experimental
    Excisional goniotomy

    Procedure: Excisional goniotomy

Interventions

  • ProcedureHydrus Microstent

    Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery

  • ProcedureIncisional goniotomy

    Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery

  • ProcedureExcisional goniotomy

    Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery

06

What researchers measure

Primary outcomes

  1. Intraocular pressure

    Time frame: 3 years

  2. Intraocular pressure-lowering medications

    Time frame: 3 years

Secondary outcomes

  1. Surgical complications

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06289491
Responsible party
Michael M. Lin, MD (Assistant Professor of Ophthalmology, Massachusetts Eye and Ear Infirmary) — Principal investigator
First posted
Mar 4, 2024
Start date
Feb 14, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2029 (estimated)
Last update
Mar 30, 2026

Study contacts

Michael M Lin, MD
Contact
michael_lin@meei.harvard.edu
617-573-3707

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion